• NMPA's 60-day default IND authorization and CDE staff expansion to 1,000+ reviewers have cut clinical trial initiation delays by 40%, making China a competitive site for global Phase I trials.
• The four accelerated pathways (BTD, Conditional Approval, Priority Review, Special Approval) have reduced NDA approval times to a median of 12-18 months, with 30+ products approved via Conditional Approval since 2018.
• Boao Lecheng's RWE integration has enabled 30+ product approvals since 2019, with a 6-month average review time for RWE-based applications, compared to 24+ months for traditional pathways.
• MRCT alignment now allows simultaneous submission to NMPA, FDA, and EMA using a single global dataset, reducing development costs by an estimated $50-100 million per program.
• NMPA's GCP inspection rate increased by 50% year-over-year in 2022, with 15% of inspections resulting in non-compliance findings, underscoring the need for robust data integrity systems.